The use of methotrexate in children with rheumatic diseases

Clinical and Experimental Rheumatology

Volumn 28, Issue 5 SUPPL. 61, 2010, Pages

  Gutierrez Suarez R ^a   Burgos Vargas, R ^a,b  

^a HOSPITAL GENERAL DE MÉXICO   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Children; DMARD; Juvenile idiopathic arthritis; Juvenile rheumatoid arthritis; Methotrexate; Treatment

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; ACICLOVIR; ADALIMUMAB; C REACTIVE PROTEIN; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; FOLIC ACID; HYDROXYCHLOROQUINE; HYPERIMMUNE GLOBULIN; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PENICILLAMINE; PLACEBO; RHEUMATOID FACTOR; UNCLASSIFIED DRUG; VARICELLA HYPERIMMUNOGLOBULIN; ANTINUCLEAR ANTIBODY; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR INHIBITOR;

ANTIINFLAMMATORY ACTIVITY; AORTA ARCH SYNDROME; AREA UNDER THE CURVE; ARTHRITIS; ARTICLE; AZOOSPERMIA; BEHCET DISEASE; BLOOD TOXICITY; CHICKENPOX; DERMATOMYOSITIS; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE COURSE; DISTRESS SYNDROME; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; ENTHESITIS; EPIGASTRIC PAIN; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; JUVENILE DERMATOMYOSITIS; JUVENILE RHEUMATOID ARTHRITIS; LEUKOPENIA; LIVER FIBROSIS; LIVER TOXICITY; LOCALIZED SCLERODERMA; LOW DRUG DOSE; NAUSEA; POLYARTHRITIS; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; REMISSION; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TERATOGENICITY; TREATMENT INDICATION; TREATMENT RESPONSE; UNDIFFERENTIATED ARTHRITIS; UVEITIS; WEGENER GRANULOMATOSIS; AORTIC ARCH SYNDROME; BEHAVIOR DISORDER; CLINICAL EFFECTIVENESS; DAS28; HERPES ZOSTER; MONOTHERAPY; PEDIATRICS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; VITAMIN SUPPLEMENTATION;

ADOLESCENT; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; BIOLOGICAL PRODUCTS; CHILD; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HUMANS; METHOTREXATE; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 78650531313     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (77)

1. PETTY RE, SOUTHWOOD TR, MANNERS P et al.: International League of Association for Rheumatology. Classification of Juvenile Idiopathic Arthritis: Second Revision, Edmonton, 2001. J Rheumatol 2004;31:390-2.
2. WALLACE CA: Current management of juvenile idiopathic arthritis. Best Pract Res Clin Rheumatol 2006;20:279-300.
3. HAINES KA: Juvenile idiopathic arthritis: therapies in the 21 st century. Bull NYU Hosp Jt Dis 2007;65:205-11.
4. HASHKES PJ, LAXER RM: Medical Treatment of Juvenile Idiopathic Arthritis. JAMA 2005;294:1671-84.
5. LOVELL DJ: Update on Treatment of Arthritis in Children New Treatments, New Goals. Bull NYU Hosp Jt Dis 2006;64:73-6.
6. MILLER LC, SISSON BA, TUCKER LB et al.: Methotrexate treatment of recalcitrant childhood dermatomyositis. Arthritis Rheum 1992;35:1143-9.
7. AL-MAYOUF S, AL-MAZYED A, BAHABRI S: Efficacy of early treatment of severe juvenile dermatomyositis with intravenous methylprednisolone and methotrexate. Clin Rheumatol 2000;19:138-41.
8. FISLER RE, LIANG MG, FUHLBRIGGE RC et al.: Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J Am Acad Dermatol 2002;47:505-11.
9. RAMANAN AV, CAMPBELL-WEBSTER N, OTA S: The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids. Arthritis Rheum 2005;52:3570-8.
10. ZULIAN F, ATHREYA BH, LAXER R et al.: Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study. Rheumatology 2006;45:614-20.
11. LI SC, FELDMAN BM, HIGGINS GC et al.: Treatment of pediatric localized scleroderma: results of a survey of North American pediatric rheumatologists. J Rheumatol 2010;37:175-81.
12. UZIEL Y, FELDMAN B, KRAFCHIK BR et al.: Methotrexate and corticosteroid therapy for pediatric localized scleroderma. J Pediatr 2000;136:91-5.
13. FITCH PG, RETTIG P, BURNHAM JM et al.: Treatment of pediatric localized scleroderma with methotrexate. J Rheumatol 2006;33:609-14.
14. GOTTLIEB BS, MILLER LC, ILOWITE NT: Methotrexate treatment of Wegener's granulomatosis in children. J Pediatr 1996;129:604-7.
15. SHETTY AK, STOPA AR, GEDALIA A: Lowdose methotrexate as a steroid-sparing agent in a child with Takayasu's arteritis. Clin Exp Rheumatol 1998;16:335-6.
16. GEDALIA A, MOLINA JF, ELLIS GS et al.: Low-dose methotrexate therapy for childhood sarcoidosis. J Pediatr 1997;130:25-9.
17. HIROHATA S, SUDA H, HASHIMOTO T: Lowdose weekly methotrexate for pro-gressive neuropsychiatric manifestations in Behcet's disease. J Neurol Sci 1998;159:181-5.
18. JORIZZO JL, WHITE WL, WISE CM et al.: Low-dose weekly methotrexate for unusual neutrophilic vascular reactions: cutaneous polyarteritis nodosa and Behçet's disease. J Am Acad Dermatol 1991;24:973-8.
19. FOELDVARI I, WIERK A: Methotrexate is an effective treatment for chronic uveitis associated with juvenile idiopathic arthritis. J Rheumatol 2005;32:362-5.
20. ABUD-MENDOZA C, STURBAUM AK, VAZQUEZ-COMPEAN R et al.: Methotrexate therapy in childhood systemic lupus erythematosus. J Rheumatol 20:1993;20:731-3.
21. SILVERMAN E: What's new in the treatment of pediatric SLE. J Rheumatol 1996;23:1657-60.
22. RAVELLI A, BALLARDINI G, VIOLA S et al.: Methotrexate therapy in refractory pediatric onset systemic lupus erythematosus. J Rheumatol 1998;25:572-5.
23. CRONSTEIN BN: The mechanism of action of methotrexate. Rheum Dis Clin North Am 1997;23:739-51.
24. DOLEZALOVA P, KRIJT J, CHLADEK J et al.: Adenosine and methotrexate polyglutamate concentrations in patients with juvenile arthritis. Rheumatology 2005;44:74-9.
25. ALBERTIONI F, FLATO B, SEIDEMAN P et al.: Methotrexate in juvenile rheumatoid arthritis. Evidence of age dependent pharmacokinetics. Eur J Clin Pharmacol 1995;47:507-11.
26. DUPUIS L, KOREN G, SILVERMAN E et al.: Influence of food on the bioavailability of oral methotrexate in children. J Rheumatol 1995;22:1570-3.
27. SINGSEN BH, GOLDBACH-MANSKY R: Methotrexate in the treatment of juvenile rheumatoid arthritis and other pediatric rheumatoid and nonrheumatic disorders. Rheum Dis Clin North Am 1997;23:811-40.
28. RAVELLI A, GERLONI V, CORONA F et al.: Oral versus intramuscular methotrexate in juvenile chronic arthritis. Italian Pediatric Rheumatology Study Group. Clin Exp Rheumatol 1998;16:181-3.
29. TUKOVA J, CHLADEK J, NEMCOVÁ D et al.: Methotrexate bioavailability after oral and subcutaneous administration in children with juvenile idiopathic arthritis. Clin Exp Rheumatol 2009;27:1047-53.
30. RUPERTO N, MURRAY KJ, GERLONI V et al.: A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 2004;50:2191-201.
31. HAREL L, WAGNER-WEINER L, POZNANSKI A et al.: Effects of methotrexate on radiologic progression in juvenile rheumatoid arthritis. Arthritis Rheum 1993;36:1370.
32. RAVELLI A, VIOLA S, RAMENGHI B, BELUFFI G, ZONTA L, MARTINI A: Radiologic progression in juvenile chronic arthritis patients treated with methotrexate. J Pediatr 1998;133:262-5.
33. MAGNI-MANZONI S, ROSSI F, PISTORIO A et al.: Prognostic Factors for Radiographic Progression, Radiographic Damage, and Disability in Juvenile Idiopathic Arthritis. Arthritis & Rheum 2003;48:3509-17.
34. NIEHUES T, LANKISCH P: Recommendations for the Use of Methotrexate in Juvenile Idiopathic Arthritis. Pediatric Drugs 2006;8:347-56.
35. ALBERS HM, WESSELS JA, VAN DER STRAATEN RJ et al.: Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritis. Arthritis Rheum 2009;61:46-51.
36. BARTOLI M, TARÒ M, MAGNI-MANZONI S et al.: The magnitude of early response to methotrexate therapy predicts long-term outcome of patients with juvenile idiopathic arthritis. Ann Rheum Dis 2008;67:370-4.
37. VILCA I, MUNITIS PG, PISTORIO A et al.: Predictors of poor response to methotrexate in polyarticular-course juvenile idiopathic arthritis: analysis of the PRINTO methotrexate trial. Ann Rheum Dis 2010 Jun. 4. [Epub ahead of print]
38. RAVELLI A, MARTINI A: Methotrexate in juvenile idiopathic arthritis: answers and questions. J Rheumatol 2000;27:1830-3.
39. GOTTLIEB BS, KEENAN GF, LU T et al.: Discontinuation of methotrexate treatment in juvenile rheumatoid arthritis. Pediatrics 1997;100:994-7.
40. RAVELLI A, VIOLA S, RAMENGHI B et al.: Frequency of relapse after discontinuation of methotrexate therapy for clinical remission in juvenile rheumatoid arthritis. J Rheumatol 1995;22:1574-6.
41. FOELL D, WULFFRAAT N, WEDDERBURN LR et al.: Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. JAMA 2010;303:2034.
42. FOELL D, FROSCH M, SCHULZEZUR WIESCH A et al.: Methotrexate treatment in juvenile idiopathic arthritis: when is the right time to stop? Ann Rheum Dis 2004;63:206-8.
43. TRUCKENBRODT H, HAFNER R: Methotrexate therapy in juvenile rheumatoid arthritis: A retrospective study. Arthritis Rheum 1986;29:801-7.
44. GIANNINI E, BREWER E, KUZMINA N et al.: Methotrexate in resistant juvenile rheumatoid arthritis: Results of the USA-USSR double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and the Cooperative Children's Study Group. N Engl J Med 1992;326:1043-9.
45. GIANNINI E, CASSIDY J, BREWER E et al.: Comparative efficacy and safety of advanced drug therapy in children with juvenile rheumatoid arthritis. Semin Arthritis Rheum 1993;23:34-46.
46. WOO P, SOUTHWOOD TR, PRIEUR AM et al.: Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oli-goarticular or systemic arthritis. Arthritis Rheum 2000;43:1849-57.
47. CÉSPEDES-CRUZ A, GUTIÉRREZ-SUÁREZ R, PISTORIO A: Methotrexate improves the health-related quality of life of children with juvenile idiopathic arthritis. Ann Rheum Dis 2008;67:309-14.
48. SILVERMAN E, MOUY R, SPIEGEL L et al.: Leflunomide or methotrexate for juvenile rheumatoid arthritis. N Engl J Med 2005;352:1655-66.
49. MAINI RN, BREEDVELD FC, KALDEN JR et al.: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor' monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63.
50. LIPSKY PE, VAN DER HEIJDE DM, ST CLAIR EW et al.: Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594-602.
51. KLARESKOG L, VAN DER Heijde D, DE JAGER JP et al.; FOR THE TRIAL OF ETANERCEPT AND METHOTREXATE WITH RADIOGRAPHIC PATIENT OUTCOMES (TEMPO) STUDY INVESTIGATORS: Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675-81.
52. LOVELL DJ, GIANNINI EH, REIFF A et al.: Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000;342:763-9.
53. LOVELL DJ, GIANNINI EH, REIFF A et al.: Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Interim results from an ongoing multicenter, open-label, extendedtreatment trial. Arthritis Rheum 2003;48:218-26.
54. QUARTIER P, TAUPIN P, BOURDEAUT F et al.: Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 2003;48:1093-101.
55. LOVELL DJ, REIFF A, OLCAY YJ et al.: Longterm safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2006;54:1987-94.
56. LOVELL DJ, REIFF A, ILOWITE NT et al.: safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 2008;58:1496-504.
57. SCHMELING H, MATHONY K, JOHN V et al.: A combination of etanercept and methotrexate for the treatment of refractory juvenile idiopathic arthritis: a pilot study. Ann Rheum Dis 2001;60:410-2.
58. GIANNINI EH, ILOWITE NT, LOVELL DJ et al.: Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum 2009;60:2794-804.
59. HORNEFF G, DE BOCK F, FOELDVARI I et al.: Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann Rheum Dis 2009 68:519-25.
60. GERLONI V, PONTIKAKI I, GATTINARA M et al.: Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor' monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis. Results of an open-label prospective study. Arthritis Rheum 2005;52:548-53.
61. RUPERTO N, LOVELL DJ, CUTTICA R et al.: A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2007;56:3096-106.
62. RUPERTO N, LOVELL DJ, CUTTICA R et al.: Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension. Ann Rheum Dis 2010;69:718-22.
63. LOVELL DJ, RUPERTO N, GOODMAN S et al.: Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008;359:810-20.
64. ORTIZ-ALVAREZ O, MORISHITA K, AVERY G et al.: Guidelines for blood test monitoring of methotrexate toxicity in juvenile idiopathic arthritis. J Rheumatol 2004;31:2501-6.
65. KOCHARLA L, TAYLOR J, WEILER T et al.: Monitoring methotrexate toxicity in juvenile idiopathic arthritis. J Rheumatol 2009;36:2813-8.
66. HASHKES PJ, BALISTRERI WF, BOVE KE et al.: The long-term effect of methotrexate therapy on the liver in patients with juvenile rheumatoid arthritis. Arthritis Rheum 1997;40:2226-34.
67. SCHMELING H, STEPHAN V, BURDACH S et al.: Pulmonary function in children with juvenile idiopathic arthritis and effects of methotrexate therapy. Z Rheumatol 2002;61:168-72.
68. VAN DER MEER A, WULFFRAATNM, PRAKKEN BJ et al.: Psychological side effects of MTX treatment in juvenile idiopathic arthritis: a pilot study. Clin Exp Rheumatol 2007;25:480-5.
69. WEST SG: Methotrexate hepatotoxicity. Rheum Dis Clin North Am 1997;23:883-915.
70. WALLACE CA: The use of methotrexate in childhood rheumatic diseases. Arthritis Rheum 1998;41:381-91.
71. KUGATHASAN S, NEWMAN AJ, DAHMS HB et al.: Liver biopsy findings in patients with juvenile rheumatoid arthritis receiving longterm, weekly methotrexate therapy. J Pediatr 1996;128:149-51.
72. GRAHAM LD, MYONES BL, RIVAS-CHACON RF et al.: Morbidity associated with long-term methotrexate therapy in juvenile rheumatoid arthritis. J Pediatr 1992;120:468-73.
73. KEIM D, RAGSDALE C, HEIDELBERGER K et al.: Hepatic fibrosis with the use of methotrexate for juvenile rheumatoid arthritis. J Rheumatol 1990;17:846-8.
74. HASHKES PJ, BALISTRERI WF, BOVE KE et al.: The relationship of hepatotoxic risk factors and liver histology in methotrexate therapy for juvenile rheumatoid arthritis. J Pediatr 1999;134:47-52.
75. PETER G (Ed.): 1997 Redbook: report of the Committee on Infectious Diseases, 24th ed. Elk Grove Village, IL, American Academy of Pediatrics, 1997.
76. ORTIZ Z, SHEA B, SUAREZ-ALMAZOR ME et al.: The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis: a metaanalysis of randomized controlled trials. J Rheumatol 1998;25:36-43.
77. HUNT PG, ROSE CD, MCILVAIN-SIMPSON G et al.: The effects of daily intake of folic acid on the efficacy of methotrexate therapy in children with juvenile rheumatoid arthritis: a controlled study. J Rheumatol 1997;24:2230-2.